LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Kodu・Aktsiate loetelu・Simulations Plus Inc

Simulations Plus Inc

Suletud

SektorTervishoid

15.7 5.87

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

14.65

Max

16.67

Põhinäitajad
By Trading Economics
Sissetulek	3.9M 4.5M
Müük	5.9M 24M
Aktsiakasum	0.35
Dividenditootlus	0.48
Kasumimarginaal	18.669
Töötajad	212
EBITDA	4.9M 7.2M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+5.61% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	0.48% 2.25%
Järgmine tulemuste avaldamine	13. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	55M 306M
Eelmine avamishind	9.83
Eelmine sulgemishind	15.7

Uudiste sentiment

By Acuity

14%

86%

19 / 347 Pingereas Healthcare

Simulations Plus Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. mai 2026, 23:41 UTC

Tulu

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6. mai 2026, 21:40 UTC

Tulu

Nutrien Logs Higher Profit, Sales Growth in 1Q

6. mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6. mai 2026, 23:34 UTC

Market Talk

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6. mai 2026, 23:13 UTC

Tulu

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6. mai 2026, 23:13 UTC

Tulu

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6. mai 2026, 23:12 UTC

Tulu

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6. mai 2026, 23:11 UTC

Tulu

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6. mai 2026, 23:11 UTC

Tulu

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6. mai 2026, 23:11 UTC

Tulu

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6. mai 2026, 23:11 UTC

Tulu

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6. mai 2026, 23:11 UTC

Tulu

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6. mai 2026, 23:11 UTC

Tulu

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6. mai 2026, 23:07 UTC

Tulu

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6. mai 2026, 23:06 UTC

Tulu

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6. mai 2026, 23:06 UTC

Tulu

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6. mai 2026, 23:05 UTC

Tulu

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6. mai 2026, 23:04 UTC

Tulu

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6. mai 2026, 22:50 UTC

Tulu

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6. mai 2026, 22:25 UTC

Market Talk

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6. mai 2026, 22:11 UTC

Tulu

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6. mai 2026, 22:11 UTC

Tulu

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6. mai 2026, 22:05 UTC

Market Talk

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6. mai 2026, 21:58 UTC

Tulu

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6. mai 2026, 21:47 UTC

Market Talk

Tulu

Costco Posts 13% Sales Growth in April -- Market Talk

6. mai 2026, 21:46 UTC

Tulu

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6. mai 2026, 21:40 UTC

Tulu

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6. mai 2026, 21:35 UTC

Market Talk

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6. mai 2026, 21:32 UTC

Kuumad aktsiad

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6. mai 2026, 21:29 UTC

Tulu

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Simulations Plus Inc Prognoos

Hinnasiht

By TipRanks

5.61% tõus

12 kuu keskmine prognoos

Keskmine 16 USD 5.61%

Kõrge 16 USD

Madal 16 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Simulations Plus Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Simulations Plus Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

19 / 347 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.